| The COVID-19 vaccine development landscape TT Le, Z Andreadakis, A Kumar, RG Román, S Tollefsen, M Saville, ... Nature reviews. Drug discovery 19 (5), 305-306, 2020 | 2324 | 2020 |
| Evolution of the COVID-19 vaccine development landscape TT Le, JP Cramer, R Chen, S Mayhew Nature Reviews Drug Discovery, 2020 | 405 | 2020 |
| Estimating the cost of vaccine development against epidemic infectious diseases: a cost minimisation study D Gouglas, TT Le, K Henderson, A Kaloudis, T Danielsen, ... The Lancet Global Health 6 (12), e1386-e1396, 2018 | 233 | 2018 |
| Status report on COVID-19 vaccines development A Kumar, WE Dowling, RG Román, A Chaudhari, C Gurry, TT Le, ... Current Infectious Disease Reports 23, 1-12, 2021 | 86 | 2021 |
| Mucosal vaccines for SARS-CoV-2: scientific gaps and opportunities—workshop report JM Knisely, LE Buyon, R Mandt, R Farkas, S Balasingam, K Bok, ... npj Vaccines 8 (1), 53, 2023 | 41 | 2023 |
| The mRNA vaccine development landscape for infectious diseases A Kumar, J Blum, TT Le, N Havelange, D Magini, IK Yoon Nat Rev Drug Discov 21 (5), 333-334, 2022 | 29 | 2022 |
| Medical countermeasures against henipaviruses: a review and public health perspective RG Román, N Tornieporth, NG Cherian, AC Shurtleff, MLA Jackson, ... The Lancet Infectious Diseases, 2021 | 20 | 2021 |
| When ready, a coronavirus vaccine must reach all A Kumar, TT Le Nature India, 2020 | | 2020 |
